fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Dextromethorphan HBR

1 general benefit · 1 not a benefit

Koffex DM · DIN 01928783 · 3 mg/mL · oral liquid

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Koffex DM · DIN 01928783 Manufacturer: Rougier Pharma, Division of Ratiopharm Inc.; listing date 1996-10-01 Health Canada: Marketed since 2013-01-11 · brand KOFFEX DM · ATC R05DA09 DEXTROMETHORPHAN · form Syrup · route Oral · ingredients DEXTROMETHORPHAN HYDROBROMIDE 15 MG/5ML · company Teva canada limited · schedule Non-prescription drugs
Re-check Health Canada status and shortages (live) · Health Canada product record

Koffex DM: Formulary list price $0.02 per unit (the source does not state the unit; exact figure $0.0190). What the ministry pays, not the patient.

Ministry pays: $0.0190 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 01928783)

Source record
DIN 01928783: Koffex DM Raw flags: sec3=Y, selfMed=Y Item: 480400010; group id 571; item number 1523; lccId None; manufacturer id ROG Source form: O/L; strength: 3mg/mL Recorded listing: General benefit; self-medication (OTC-type) product Source prices (unrounded): $0.0190; ministry $0.0190 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=01928783 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=11848
Interchangeable products
DM-Syrup · DIN 00391069 · not recorded
Shortage status: resolved shortage (ended October 3, 2023); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01928783
Shortage record checked October 6, 2026

DM-Syrup · PIN 00391069 · 3 mg/mL · oral liquid

Listed, not a benefitOntario PIN; no Health Canada record under this code
StatusListed, not a benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.

No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp

Check Health Canada brand search
1 brand, same coverage
DM-Syrup · DIN 00391069 Manufacturer: Parke-Davis,Division Warner-Lambert Canada Inc.; listing date 2006-06-15 No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Re-check Health Canada status and shortages (live)

DM-Syrup: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Ontario PIN; see Health Canada brand lookup · Verify on the e-Formulary ↗ (DIN 00391069)

Source record
DIN 00391069: DM-Syrup Raw flags: notABenefit=Y, sec3=Y Item: 480400010; group id 571; item number 1523; lccId None; manufacturer id PDA Source form: O/L; strength: 3mg/mL Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00391069 Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Interchangeable products
Koffex DM · DIN 01928783 · $0.0190
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00391069
Shortage record checked October 6, 2026

Other products in the same Health Canada class (R05DA): coverage varies; not interchangeable

  • Hydrocodone bitartrate (Hycodan): general benefit, not a benefit
Other drugs in the same formulary class (48:04 Antitussives) and how they are covered

Matched class: 48:04 Antitussives

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Some products covered without a code (check the product listing): HYDROCODONE BITARTRATE 48:04 Antitussives

HYDROCODONE BITARTRATE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 1mg/mL · O/L Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 48:04
Full class listing Related classes: 48:08 Expectorants Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
Product monograph unavailable: no link

Other review policies

For DM-Syrup: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026